organization · Reporting owner
Omega Fund IV G.P. Manager, Ltd.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kezar Life Sciences, Inc.
Report date June 25, 2018 · Filed June 25, 2018
Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Stampacchia Otello, Lim Richard J., Paster Anne-Mari
Section 16 reporting ended · disclosed 2018-06-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 315,489 |
Reported balance
After 2018-06-25 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. |
| Common StockSEC Table I · non-derivative | Direct | 693,272 |
Reported balance
After 2018-06-25 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Omega IV | 693,272 |
Last balance in matching sequence
After 2018-06-25 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2018-06-25 · Conversion · Acquired 315,489 · Balance 315,489 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Row 4 · 2018-06-25 · Conversion · Acquired 377,783 · Balance 693,272 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega IV | 0 |
Reported balance
After 2018-06-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-25 · Conversion · Disposed 315,489 · Balance 0 F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega IV | 0 |
Reported balance
After 2018-06-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-06-25 · Conversion · Disposed 377,783 · Balance 0 F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date.
F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein.
F3: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date.
Replimune Group, Inc.
Report date March 14, 2022 · Filed March 17, 2022
Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Stampacchia Otello
Section 16 reporting ended · disclosed 2022-03-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Otello Stampacchia | 4,763,380 |
Last balance in matching sequence
After 2022-03-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-03-14 · Exercise / conversion · Acquired 16,500 · Balance 4,779,880 F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager. Row 2 · 2022-03-14 · Sale · Disposed 16,500 · Balance 4,763,380 F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager. |
| Common StockSEC Table I · non-derivative | Direct | 4,673,380 |
Last balance in matching sequence
After 2022-03-16 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 3 · 2022-03-15 · Sale · Disposed 45,000 · Balance 4,718,380 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Row 4 · 2022-03-16 · Sale · Disposed 6,238 · Balance 4,712,142 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Row 5 · 2022-03-16 · Sale · Disposed 38,762 · Balance 4,673,380 F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.78 · Expires 2030-04-01 | IndirectBy Otello Stampacchia | 16,500 |
Reported balance
After 2022-03-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-14 · Exercise / conversion · Disposed 16,500 · Balance 16,500 F3: Stock options vested 100% on April 1, 2021. F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any.
F2: The reported securities are held directly by Otello Stampacchia, a shareholder and director of Omega Fund IV GP Manager.
F3: Stock options vested 100% on April 1, 2021.
Translate Bio, Inc.
Report date July 02, 2018 · Filed July 03, 2018
Jointly reported with Omega Fund IV, L.P., Omega Fund IV GP, L.P., Omega Fund V, L.P., Omega Fund V GP, L.P., Omega Fund V GP Manager, Ltd., Stampacchia Otello, Lim Richard J., Paster Anne-Mari, Nessi Claudio
Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 979,179 |
Reported balance
After 2018-07-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Common StockSEC Table I · non-derivative | Direct | 1,458,424 |
Reported balance
After 2018-07-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Omega IV | 979,179 |
Reported balance
After 2018-07-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-07-02 · Conversion · Acquired 979,179 · Balance 979,179 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Omega V | 1,458,424 |
Reported balance
After 2018-07-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-07-02 · Conversion · Acquired 1,458,424 · Balance 1,458,424 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega IV | 0 |
Reported balance
After 2018-07-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-02 · Conversion · Disposed 2,500,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega IV | 0 |
Reported balance
After 2018-07-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-07-02 · Conversion · Disposed 1,676,348 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega IV | 0 |
Reported balance
After 2018-07-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-07-02 · Conversion · Disposed 1,263,484 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega V | 0 |
Reported balance
After 2018-07-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-07-02 · Conversion · Disposed 5,800,000 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega V | 0 |
Reported balance
After 2018-07-02 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-07-02 · Conversion · Disposed 2,000,103 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Omega V | 0 |
Reported balance
After 2018-07-02 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-07-02 · Conversion · Disposed 302,173 · Balance 0 F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
F2: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
F3: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries A Preferred Stock · Derivative | 5,800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 12 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega V Disclosed balance after: 0 Underlying: Common Stock · 1,044,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3 · ownership.direct: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries A Preferred Stock · Derivative | 5,800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 11 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,044,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries C Preferred Stock · Derivative | 1,263,484 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 10 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 0 Underlying: Common Stock · 227,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries C Preferred Stock · Derivative | 1,263,484 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 9 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 227,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries B Preferred Stock · Derivative | 1,676,348 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 8 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 0 Underlying: Common Stock · 301,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries B Preferred Stock · Derivative | 1,676,348 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 7 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries A Preferred Stock · Derivative | 2,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 6 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 0 Underlying: Common Stock · 450,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionSeries A Preferred Stock · Derivative | 2,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · derivative · entry 5 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionCommon Stock | 1,458,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 4 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega V Disclosed balance after: 1,458,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3 · ownership.direct: The reported securities are beneficially owned by Omega Fund V GP, L.P. ("Omega V GP"), as general partner of Omega Fund V, L.P. ("Omega V"). Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), is the general partner of Omega V GP. Otello Stampacchia, Richard Lim, Anne-Mari Paster and Claudio Nessi are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionCommon Stock | 1,458,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 3 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionCommon Stock | 979,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 2 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 979,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of the Reporting Persons disclaim beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein, if any. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:44 UTC | Translate Bio, Inc. TBIO · Entity 135439 | ConversionCommon Stock | 979,179 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-019324 · doc4.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Lim Richard J. · CIK 0001623720 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 377,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 8 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 0 Underlying: Common Stock · 377,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.exercise_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.expiration_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 377,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 7 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 377,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.exercise_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.expiration_date: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 315,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 6 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 0 Underlying: Common Stock · 315,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F1 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F1 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries A Redeemable Convertible Preferred Stock · Derivative | 315,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · derivative · entry 5 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F1 · derivative.exercise_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F1 · derivative.expiration_date: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 377,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 4 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 693,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 377,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 3 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Redeemable Convertible Preferred Stock ("Series B") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the IPO. The Series B had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 315,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 2 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Omega IV Disclosed balance after: 315,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. F2 · ownership.direct: The reported securities are beneficially owned by Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega Fund IV, L.P. ("Omega IV"). Omega Fund IV G.P. Manager, Ltd. ("Omega IV GP Manager"), is the general partner of Omega IV GP. Otello Stampacchia, Richard Lim and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega Fund IV, L.P. Each of the Reporting Persons disclaims beneficial ownership of these securities, except to the extent of his, her or its pecuniary interest therein. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 19:07 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 315,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017995 · doc4.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · Former 10% Owner Omega Fund IV GP, L.P. · CIK 0001528383 · Former 10% Owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · Former 10% Owner Stampacchia Otello · CIK 0001361712 · Former 10% Owner Lim Richard J. · CIK 0001623720 · Former 10% Owner Paster Anne-Mari · CIK 0001652863 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Redeemable Convertible Preferred Stock ("Series A") converted automatically into shares of the issuer's common stock on a one-for-one basis upon the completion of the issuer's public offering of common stock pursuant the issuer's amended registration statement under the Securities Act of 1933, as amended, filed with the Commission on June 18, 2018 (the "IPO"). The Series A had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.